MDS | Tumor

CURE’s myelodysplastic syndrome (MDS) page is an extensive resource of cancer information featuring the latest myelodysplastic syndrome news, expert oncologist insights on the latest cancer treatments, oncology research, advocacy efforts, and medical data on MDS.

Safety Profile of Lower-Dose Oral Onureg Remains Consistent in Lower-Risk MDS

June 3rd 2024, 1:00pm

Article

The safety profile of 200 milligrams and 300 milligrams of oral Ongureg were similar in patients with lower- to intermediate-risk MDS.

Cancer Remission Is Wonderful But Scary

May 27th 2024, 5:00pm

Article

I’ve experienced mixed emotions during my periods of remission for my myelodysplastic syndrome.

Cancer and Fatigue Go Together

May 15th 2024, 5:00pm

Article

As a cancer survivor, I’m pleading for more research on cancer related fatigue.

Cancer Survivors Can Get Tired of Being Called ‘Strong’

April 27th 2024, 5:00pm

Article

I must admit when people call us cancer survivors "strong," it's a double-edged sword.

Early Transfusions, Treatments May Improve Outcomes in Low-Risk MDS

April 25th 2024, 7:00pm

Article

Receiving early transfusions and treatment to reduce transfusion dependency significantly improves survival and quality of life in low-risk MDS.

How COVID-19 Helped Me Cope Day to Day With Cancer

April 11th 2024, 5:00pm

Article

I was surprised that COVID-19 taught me how to cope with the daily annoyances of cancer.

Elritercept Receives FDA Fast Track Designation for MDS Treatment

March 22nd 2024, 1:00pm

Article

The novel treatment elritercept received a Fast Track designation from the FDA to treat anemia in patients with MDS.

Blood Cancer Drug Decreases Levels of Anti-Fungal Medication

March 19th 2024, 9:00pm

Article

Patients taking Tibsovo to treat MDS or AML may want to discuss the appropriate medications to treat and prevent infections, an expert said.

FDA Committee in Favor of Imetelstat for Transfusion-Dependent MDS

March 15th 2024, 7:00pm

Article

The Oncologic Drug Advisory Committee voted that the benefits of imetelstat outweigh the risks for transfusion-dependent myelodysplastic syndrome and anemia.

Follow-Ups Help Prevent ‘Dangerous’ Outcomes in Blood Cancer Survivors

March 8th 2024, 8:00pm

Article

Attending follow-up appointments as blood cancer survivors can help prevent more dangerous outcomes, including secondary cancers, an expert told CURE®.